Starlims

STARLIMS Corporation
FormerlyAbbott Informatics (2014–2021)
Company type
Private
IndustrySoftware, IT
Founded1986; 40 years ago (1986)
Founders
  • Itschak Friedman
  • Dinu Toiba
Headquarters
Hollywood, Florida
,
U.S.
Key people
Trey Cook (CEO)
OwnerTurn/River Capital
Websitewww.starlims.com

STARLIMS Corporation (STARLIMS) is a portfolio company of Turn/River Capital that provides web-based laboratory information management systems.

History

The company was founded by Itschak Friedman and Dinu Toiba in Israel in 1986, and developed and sold LIMS software. The company was renamed to STARLIMS.[1] By 2005, the company's software was installed at the US Centers for Disease Control and Prevention and in systems of state health authorities in 12 US states.[2] The company held its IPO in the US in 2007.[3] Friedman was CEO until the company was acquired by Abbott Laboratories in 2009 for $123 million; at that time the company had 160 employees and most of its operations and sales were in the US, the UK, and Hong Kong.[1] By the time of the sale, STARLIMS was offered as a web application.[4] Abbott intended to fold STARLIMS' products offerings into its other health information technology businesses in an effort to improve its clinical diagnostics business.[4] In 2014, Abbott changed the subsidiary's name from STARLIMS to Abbott Informatics.[5][6] In July 2021 Abbott sold STARLIMS to Francisco Partners.[7]

In August 2023, it was announced STARLIMS had acquired the London-based R&D Electronic Laboratory Notebook (ELN) platform, Labstep for an undisclosed amount.[8]

In January 2026, it was announced that Francisco Partners had sold Starlims to private-equity firm Turn/River Capital for an undisclosed amount.[9]

References

  1. ^ a b Zalik, Nir (16 December 2009). "Abbott Buying STARLIMS Corp". Haaretz. Archived from the original on 5 January 2018. Retrieved 29 May 2017.
  2. ^ Gavison, Yoram (8 April 2005). "LIMS Boasts String of Major Contracts". Haaretz. Archived from the original on 5 January 2018. Retrieved 29 May 2017.
  3. ^ Gelsi, Steve (May 4, 2007). "Starlims Tech files $37 mln IPO". MarketWatch.com. Archived from the original on August 13, 2023. Retrieved November 20, 2008.
  4. ^ a b Elaine, Meyer (December 15, 2009). "Abbott To Buy STARLIMS In $123M Cash Deal - Law360". Law360. Archived from the original on January 4, 2018. Retrieved May 29, 2017.
  5. ^ "Abbott Informatics Europe Limited - Filing history". Companies House. Archived from the original on 4 January 2018. Retrieved 29 May 2017.
  6. ^ "Change of Name notice". Florida Department of State Corporations Division. 30 May 2014. Archived from the original on 4 January 2018. Retrieved 29 May 2017.
  7. ^ Weitzman, Aaron (March 9, 2023). "State of play: Lab informatics". Axios. Archived from the original on March 30, 2023. Retrieved May 1, 2023.
  8. ^ FinSMEs (2023-08-25). "Starlims Acquires Labstep". FinSMEs. Retrieved 2023-08-25.
  9. ^ Kreutzer, Laura (January 13, 2026). "Francisco Partners Extends Exit Run With Starlims Sale". The Wall Street Journal. Retrieved January 20, 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.